Understanding genetic risks of severe skin reactions to medications
Official title: A Translational Bioinformatics Approach for Phenotyping and Genetic Risk of Severe Cutaneous Adverse Drug Reactions
Funded at Vanderbilt University Medical Center · NIH-11138152 · Data updated 2026-11-12
This study is looking at why some people have serious skin reactions when taking vancomycin, a common antibiotic, by checking their genetic and health information, so we can help doctors make safer choices for their patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Vanderbilt University Medical Center NIH-funded |
| Lab location | 1 site (Nashville, United States) |
| Project start | January 15, 2025 |
| Project end | December 31, 2029 |
| Funding year | 2025 |
| Award (this year) | $186,332 |
| NIH project number | 1K08AI185260-01A1 |
| Project ID | NIH-11138152 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals who have been prescribed vancomycin and have a genetic predisposition to adverse drug reactions.
✕Less likely to help
Patients who have not been prescribed vancomycin or do not carry the genetic markers associated with DRESS may not benefit from this research.
What this research studies
This research investigates severe skin reactions, specifically Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), that can occur in patients taking vancomycin, a common antibiotic. By analyzing genetic and health data from patients, the study aims to identify risk factors that contribute to these adverse reactions. The approach utilizes advanced bioinformatics techniques to link genetic information with clinical outcomes, helping to uncover why some individuals are more susceptible to these severe reactions. The ultimate goal is to enhance patient safety by informing better prescribing practices and developing personalized treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to improved identification of patients at risk for severe drug reactions, allowing for safer medication use.
How similar studies have gone: Previous research has shown success in using genetic and bioinformatics approaches to identify risk factors for drug reactions, indicating that this methodology is promising.
Where this research is happening
-
Vanderbilt University Medical Center
Nashville, United States Active
Researchers
- Principal investigator: Krantz, Matthew Steven — Vanderbilt University Medical Center
- Study coordinator: Krantz, Matthew Steven
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.